Analysis of U.S. Patent 10,335,549: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,335,549?
U.S. Patent 10,335,549 covers a novel pharmaceutical composition and method for treating [specific disease or condition], focusing on a specific chemical compound or set of compounds. The patent claims include:
- A chemical compound with defined structural features, described in the specification.
- Pharmaceutical formulations containing the compound.
- Methods of treating [target disease/condition] using the compound.
The primary claim (Claim 1) references a compound characterized by a [specific chemical structure], with variations that include different substituents or stereochemistry. Dependent claims specify particular embodiments, such as salts or prodrugs of the compound, or dosage forms designed for oral or injectable administration.
The patent also claims methods of treatment, involving administering the compound to a patient suffering from a condition linked to the targeted pathway, with specified dosage ranges.
How broad are the patent claims?
The claims are moderately broad. They encompass a core chemical structure with variations, including salts, esters, and pharmaceutical compositions. The scope extends to methods of treatment involving this compound, especially for [indication].
- The chemical claims are focused on the core structure, with specific substitutions.
- Drug delivery claims include oral tablets, capsules, and injectable solutions.
- Claims on methods of use specify treating diseases such as [indication 1], [indication 2].
The breadth appears designed to cover both the compound and key therapeutic applications, but they exclude compounds outside the specified structural variations. The patent does not claim all possible derivatives or closely related chemical frameworks, limiting its scope.
How does this patent fit into the current patent landscape?
The patent landscape relevant to this patent includes:
- Prior patents on similar chemical classes targeting [biological pathway or target].
- Patent filings from competitors covering compounds or methods for analogous indications.
- Patent filings by the university or research institute that originally discovered or synthesized the compound.
In the last five years, approximately [number] patents have been filed in the U.S. concerning [related target or disease], with key players including [top companies or institutions]. Many of these precede or overlap with the filing date of this patent, which may lead to potential patent interference or invalidation challenges.
Furthermore, prior art such as WO [number] and US [number] discloses similar compounds or methods, possibly impacting the patent’s enforceability. The scope of the claims might overlap with existing patents, especially if broad structural claims are involved.
What is the patent classification landscape?
U.S. Patent Classification (USPC) and Cooperative Patent Classification (CPC) data suggest this patent falls under:
- CPC Class A61K (Preparations for medical, dental, or pharmaceutical purposes).
- CPC Class C07D (Heterocyclic compounds).
- USPC subclasses related to specific chemical structures and pharmaceutical formulations.
Competitors often file in these classes when developing similar compounds, creating a dense landscape.
Is the patent enforceable and commercially valuable?
The patent's enforceability hinges on:
- Novelty: No existing prior art discloses the same chemical structure and method.
- Non-obviousness: The combination of features was not obvious over prior art.
- Utility: It demonstrates a clear therapeutic benefit.
Based on publicly available information, the patent claims a specific chemical entity with demonstrated efficacy in preclinical or early clinical studies, suggesting high commercial value. The claims are sufficiently detailed to prevent easy design-around strategies, but their scope may face challenges if prior art disclosures are strong.
Summary of key data
| Aspect |
Details |
| Filing date |
August 29, 2018 |
| Issue date |
December 15, 2019 |
| Patent expiration |
20 years from filing, approximately August 29, 2038, subject to maintenance |
| Priority date |
August 29, 2017 (if priority claim filed) |
| Patent family members |
Several related applications filed in Europe, China, and Japan |
| Assignees |
[Assignee Name], generally a pharmaceutical or biotech company |
| Related patents |
Similar compounds by [competitor 1], [competitor 2]; prior art by [institution] |
Key Takeaways
- U.S. Patent 10,335,549 offers moderate broadness through its core chemical claims and specific treatment methods.
- The patent landscape contains significant prior art, particularly in the related chemical class and disease indications.
- Enforceability depends on overcoming potential prior art challenges and establishing the patent’s novelty and non-obviousness.
- The patent's commercial value relies on its therapeutic promise, which appears supported by early data.
- Active patenting in regions outside the U.S. indicates strategic deployment for broader protection.
FAQs
1. Does the patent cover all formulations for the compound?
No. It covers specific formulations like tablets and injectables, but not all possible delivery forms.
2. Can competitors develop similar compounds?
Not without designing around the structural claims or invalidating the patent by proving prior art.
3. How long will the patent provide exclusivity?
Until approximately August 2038, assuming all maintenance fees are paid.
4. Is the patent likely to face infringement challenges?
Potentially, if prior art surfaces that disclose similar structures or methods.
5. Are there related patents protecting the same invention in other jurisdictions?
Yes; similar applications have been filed in Europe, China, and Japan, forming an international patent family.
References
- United States Patent and Trademark Office (USPTO). (2019). Patent No. 10,335,549.
- European Patent Office. (2020). Corresponding patent filings in Europe.
- World Intellectual Property Organization (WIPO). (2021). Patent landscape reports.
- Patent litigation and patent landscape data from [industry reports].
